Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; hypromellose; maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.,hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - dydrogesterone, quantity: 10 mg; estradiol, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; colloidal anhydrous silica; lactose monohydrate; maize starch; titanium dioxide; iron oxide yellow; purified talc; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hypromellose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone; estradiol as hemihydrate - film coated tablets - dydrogesterone 2.5 mg; estradiol as hemihydrate 0.5 mg - dydrogesterone and estrogen - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women at least 12 months since last menses.femoston is indicated for women with an intact uterus

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone; estradiol as hemihydrate - film coated tablets - dydrogesterone 5 mg; estradiol as hemihydrate 1 mg - dydrogesterone and estrogen - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women at least 12 months since last menses.prevention of osteoporosis in postmenopausal women at high risk of future fractures. femoston contini 1/5 should only be used in patients who are intolerant of other products, approved for the prevention of osteoporosis or for whom these products are contra-indicated.femoston is indicated for women with an intact uterus

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - dydrogesterone; estradiol; estradiol - film coated tablets - dydrogesterone 10 mg; estradiol 1 mg; estradiol 1 mg - dydrogesterone and estrogen - hormone replacement therapy (hrt) for estrogen deficiency symptoms in menopausal women at least 6 months since last menses.prevention of osteoporosis in postmenopausal women at high risk of future fractures. femoston 1/10 should only be used in patients who are intolerant of other products, approved for the prevention of osteoporosis or for whom these products are contra-indicated.femoston is indicated for women with an intact uterusexperience with treatment of women older than 65 years is limited.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - oestradiol; dydrogesterone -

Kenya - English - Pharmacy and Poisons Board

abbott laboratories s.a. (pty) ltd 219 golf club terrace constantia kloof , - oestradiol/ dydrogesterone - tablet - femoston 1/10 contains 14 tablets with 1 mg… - hormonal contraceptives: progestogens for

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - dydrogesterone; estradiol - oral tablet - 5mg ; 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - estradiol; dydrogesterone - oral tablet - 500microgram ; 2.5mg